WSJ : More Cooking, Less Shampooing: The Coronavirus Consumer Starts to Emerge

More Cooking, Less Shampooing: The Coronavirus Consumer Starts to Emerge
Unilever, P&G, other consumer-goods giants report major shifts in shopper behavior amid lockdowns

Consumers are cooking and cleaning more while spending less time and money on grooming and makeup, the world’s biggest consumer-products companies say, as a picture emerges of how the coronavirus is reshaping lifestyles.

The question executives and investors now face is which behaviors will stick when restrictions to fight the pandemic lift, and which will fade.

“People we know will continue to wash their hands more. Probably they’ll have more concern for surface hygiene in homes,” said Unilever PLC Chief Executive Alan Jope on Thursday. “That whole hygiene thing will carry on.”

Consumers are cooking and cleaning more while spending less time and money on grooming and makeup, the world’s biggest consumer-products companies say, as a picture emerges of how the coronavirus is reshaping lifestyles.

The question executives and investors now face is which behaviors will stick when restrictions to fight the pandemic lift, and which will fade.

“People we know will continue to wash their hands more. Probably they’ll have more concern for surface hygiene in homes,” said Unilever PLC Chief Executive Alan Jope on Thursday. “That whole hygiene thing will carry on.”

Chief Financial Officer Graeme Pitkethly said people are using personal-care products such as shampoo and deodorant less, estimating 11 fewer uses in a typical week. Makeup giant L’Oréal last week said the global cosmetics market was down 8% in the first quarter as consumers pull back on skin care and beauty products.

On the flip side, people are cooking more at home, buoying demand for brands such as Knorr soup cubes, Hellmann’s mayonnaise and Pot Noodle instant noodles, Unilever said.

“We underestimated initially the positive impact this would have on our business for at-home cooking,” said Mr. Jope. “Those center-of-the-grocery-store businesses that have been a bit flat for many years, all of those are seeing a rejuvenation.”

Spending time at home has driven up demand for toilet paper, propelling Cottonelle owner Kimberly Clark Corp. to start repurposing its manufacturing capacity to make more of the softer, thicker toilet paper used at home versus what’s typically used in offices.

One change seen as likely to be long-lasting is the shift to online shopping. Online sales—which make up about 6% to 7% of Unilever’s business—grew 36% in the quarter, as consumers under lockdown ordered more via the internet. Unilever said it plans to ramp up investments in selling directly to consumers.

“I think we will be able to look back and see this as a point of inflection for online grocery shopping,” said Mr. Jope.

Target Corp. this week said traffic to stores had slowed considerably as states imposed lockdown orders, with consumers shifting to online buying. Target has seen strong sales of food, household goods and, more recently, office supplies and cooking appliances, while sales of apparel and accessories have fallen.

Longer-term, shoppers will “embrace routines developed during these weeks at home with their families,” said Target Chief Executive Brian Cornell. Target’s model of using stores as online delivery and pickup hubs “will continue to serve us well,” he said.

Domino’s Pizza Inc. on Thursday reported a rise in U.S. sales in recent weeks as consumers ordered pizza to eat at home rather than go out. Last month, it said it would hire more than 10,000 workers to meet rising demand amid the pandemic.

Lockdowns have forced restaurants to close in many countries. That has hurt sales for Unilever’s food-services arm, which sells ingredients to restaurants, and executives at the company signaled they think sales could be slow to return.

In China, 70% of closed restaurants have reopened but are running at between 50% and 70% capacity because of social-distancing protocols, said Mr. Pitkethly. He signaled some form of social distancing would likely remain in place through the end of the year in many countries, which would continue to cap sales.

Another shift has been the decline in ice cream sales at parks, beaches and other locations that aren’t grocery stores. These make up 40% of Unilever’s ice cream business, the world’s largest with €6 billion of annual sales. The company reported a 1.7% drop in underlying sales for its food-and-refreshments unit. It is ramping up partnerships with food-delivery companies to allow consumers to order ice cream along with their takeout.

Evian owner Danone SA on Thursday said its bottled water sales for the quarter had dropped 7.4% as it, too, was hurt by similar closures.

Overall, Unilever said sales for the first three months of the year were flat, at €12.4 billion ($13.4 billion).

Unilever’s performance contrasts with that of P&G, which last week reported organic sales growth of 6% as stockpiling of laundry detergent, toilet paper and other essentials in the U.S. more than offset a slump in China.

What companies sell and where they sell it explains some of that diversion in performance. Unilever sells food, while the others don’t. It also makes most its sales from emerging markets where consumers haven’t stockpiled like they have in the West.

Unilever reported strong sales in North America, with underlying growth of 4.8%, driven by stockpiling.

“People have got bigger houses, bigger pantries, everything’s bigger in the States, and they certainly went for household stocking in the biggest way around the world,” said Mr. Pitkethly.

“There is no such thing yet as a new normal,” said Mr. Jope. “Businesses and commentators who have professed too much wisdom and insight on what the world will look like on the other side of coronavirus have come to eat humble pie.”

FT : Gilead antiviral drug remdesivir flops in first trial

Gilead antiviral drug remdesivir flops in first trial
Exclusive: Disappointing results revealed in draft documents published accidentally by WHO

A potential antiviral drug for the coronavirus has flopped in its first randomised clinical trial, disappointing scientists and investors who had high hopes for remdesivir, according to draft documents published accidentally by the World Health Organization and seen by the Financial Times.

The Chinese trial showed remdesivir — developed by California-based Gilead Sciences — did not improve patients’ condition or reduce the pathogen’s presence in the bloodstream. Researchers studied 237 patients, giving the drug to 158 and comparing their progress with the remaining 79. The drug also showed significant side effects in some, which meant 18 patients were taken off it.

The WHO said the draft document, which is undergoing peer review, was published early in error. “In response to WHO asking for information and studies to be shared early, a draft document was provided by the authors to WHO and inadvertently posted on the website and taken down as soon as the mistake was noticed,” it said. 

Gilead warned that the post included “inappropriate characterisations of the study”. 

“Importantly, because this study was terminated early due to low enrolment, it was underpowered to enable statistically meaningful conclusions,” it said. “As such, the study results are inconclusive, though trends in the data suggest a potential benefit for remdesivir, particularly among patients treated early in disease.”

Until now, evidence from the use of Gilead’s remdesivir in Covid-19, the disease caused by the new coronavirus, had relied on studies that did not meet the robust scientific standards of being randomised and having a control arm. 

There are multiple ongoing Phase 3 studies that are designed to provide the additional data needed to determine the potential for remdesivir as a treatment for Covid-19. These studies will help inform whom to treat, when to treat and how long to treat with remdesivir. The studies are either fully enrolled for the primary analysis or on track to fully enrol in the near future.

Positive feedback from a clinical trial being conducted at the University of Chicago, leaked last week, buoyed the entire stock market as investors looked for any sign that the availability of a successful drug could help open up locked down economies. 

“In this study of hospitalised adult patients with severe Covid-19 that was terminated prematurely, remdesivir was not associated with clinical or virological benefits,” the filing said.

The WHO collates current trials for possible Covid-19 interventions on a website titled “landscape analysis of candidate therapeutics for Covid-19.” A previous version of the website, which contained five pages and a column called “outcomes,” is no longer available. The new one only contains four pages and no “outcome” column.

The study was terminated early because of a lack of patients. It was conducted in China, which after a surge in cases earlier this year has seen a taper in the number of those affected. 

Earlier this month, a study in the New England Journal of Medicine showed early positive results for remdesivir, with 68 per cent of patients improving on the drug. However, the study was not an official trial but rather the collation of data from patients who had been given the drug on a “compassionate use” basis — and was not compared to any control arm. The scientists behind the study and Gilead warned at the time that it was not conclusive. 

There had been other positive signs too. Early impressions from a study showed rapid recoveries in almost all of the more than a hundred severely ill patients, when they were leaked to healthcare industry publication Stat news.

A recent US National Institutes of Health animal study also found the drug was effective at treating the disease in monkeys, when taken early in its progression.

Much larger randomised controlled trials are under way, comparing remdesivir with controls, which in Covid-19 usually means standard care for a respiratory illness, and to other drugs including the antimalarial hydroxychloroquine.

Gilead originally developed remdesivir as a treatment for Ebola, where it showed promise at stopping the virus from replicating in clinical trials, but it has never been approved.

>>>> US Gapping down

Gapping down
In reaction to disappointing earnings/guidance
:

  • NTGR -10%, CROX -7.7%, SAM -6.4%, GGG -5.9%, FTI -5.6%, XLNX -5.4%, DFS -5.1%, CTXS -3.1%, STX -2.9%, AMTD -2.9%, UN -2.4%, HSY -2.4%, CS -1.8%, DPZ -1.5%, LRCX -1.4%, CLB -1.1%, LSTR -0.8%, MC -0.6%

Other news:

  • LZB -21.2% (provides manufacturing and retail update)
  • VFF -2.4% (files for $200 mln mixed securities shelf offering)
  • GO -1.6% (prices upsized secondary offering of 15 mln shares of common stock at $34.00 per share)
  • KAI -1.5% (announces realignment of operating segments)
  • TW -1% (prices follow-on offering of 11,161,083 shares of its common stock at $50.25 per share)

Analyst comments:

  • COUP -4.4% (downgraded to Underweight from Neutral at JP Morgan)
  • TWLO -2.8% (downgraded to Neutral from Overweight at JP Morgan)
  • CHEF -1.6% (downgraded to Market Perform from Outperform at BMO Capital Marketst )
  • BIIB -1.4% (downgraded to Underperform from Mkt Perform at Raymond James)
  • ADSK -0.7% (downgraded to Neutral from Overweight at Atlantic Equities)

>>> US Gapping up

Gapping up
In reaction to strong earnings/guidance
:

  • PHR +18.2%, SNBR +16.8%, HLX +16.8%, PLXS +9.5%, LVS +9.2%, RS +6.7%, CAR +5.4% (provides preliminary Q1 results; gives update on April trends), PTEN +5.2%, BX +4.7%, GTLS +4.3%, HUD +4.2%, AA +3.8%, CDE +3.5%, WST +2.9%, POOL +2.8%, FNF +2.4%, SUI +2.3%, ORLY +1.9%, CSX +1.8%, PHM +1.8%, LLY +1.4%, TSCO +1.3%, ALLE +1%

Other news:

  • AVXL +13.6% (announces publication of clinical data for ANAVEX2-73 in Alzheimer's disease)
  • DVAX +11.1% (announces collaboration to advance COVID-19 vaccine development)
  • FLR +9.9% (selected for 8-yr position on Air Force Contract Augmentation Program V)
  • TTEK +5.6% (awarded $90 mln contract by US Air Force)
  • QDEL +1.8% (has applied for an Emergency Use Authorization for the Lyra Direct SARS-CoV-2 Assay)
  • GOOD +1.8% (provides update related to COVID-19)
  • OBSV +1.8% (announces publication of abstracts from Phase 2b EDELWEISS trial)

Analyst comments:

  • NLS +8.7% (upgraded to Buy from Hold at SunTrust)
  • ATRA +2% (upgraded to Buy from Neutral at Citigroup)
  • CMG +1.9% (upgraded to Market Perform from Underperform at BMO Capital Markets)
  • CHUY +1.6% (upgraded to Market Perform from Underperform at BMO Capital Markets)

>>> US Early premarket gappers

Early premarket gappers

  • Gapping up:
    • HLX +17.5%, SNBR +16.9%, DVAX +10.5%, LVS +10.2%, PLXS +9.5%, FLR +8.2%, PHR +7.3%, TTEK +5.6%, AA +5%, HUD +4.2%, ORLY +3.2%, FNF +2.4%, SUI +2.3%, GOOD +2.2%, CSX +2.1%, CAR +1.4%, QDEL +1%
  • Gapping down:
    • LZB -21.2%, MC -9.5%, SAM -8.2%, GGG -5.9%, FTI -5.7%, STX -5.4%, XLNX -4.1%, AMTD -3.5%, GO -2.6%, VFF -2.4%, TW -2.4%, DFS -2.1%, KAI -1.5%, LRCX -1.4%, LSTR -0.8%, CLB -0.7%, NWE -0.6%, SLM -0.6%